These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24626633)

  • 1. Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies.
    Wisely EV; Xiang YK; Oddo S
    Hum Mol Genet; 2014 Aug; 23(15):4024-34. PubMed ID: 24626633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.
    Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E
    BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
    Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
    Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.
    Rockenstein E; Overk CR; Ubhi K; Mante M; Patrick C; Adame A; Bisquert A; Trejo-Morales M; Spencer B; Masliah E
    PLoS One; 2015; 10(3):e0121570. PubMed ID: 25803611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.
    Rockenstein E; Ubhi K; Trejo M; Mante M; Patrick C; Adame A; Novak P; Jech M; Doppler E; Moessler H; Masliah E
    BMC Neurosci; 2014 Jul; 15():90. PubMed ID: 25047000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.
    McKenzie-Nickson S; Chan J; Perez K; Hung LW; Cheng L; Sedjahtera A; Gunawan L; Adlard PA; Hayne DJ; McInnes LE; Donnelly PS; Finkelstein DI; Hill AF; Barnham KJ
    ACS Chem Neurosci; 2018 Nov; 9(11):2731-2740. PubMed ID: 29920069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease.
    Branca C; Wisely EV; Hartman LK; Caccamo A; Oddo S
    Neurobiol Aging; 2014 Dec; 35(12):2726-2735. PubMed ID: 25034342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.
    Wen Y; Planel E; Herman M; Figueroa HY; Wang L; Liu L; Lau LF; Yu WH; Duff KE
    J Neurosci; 2008 Mar; 28(10):2624-32. PubMed ID: 18322105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Threonine
    Moszczynski AJ; Yang W; Hammond R; Ang LC; Strong MJ
    Acta Neuropathol Commun; 2017 Jan; 5(1):6. PubMed ID: 28077166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.
    Zhang X; Hernandez I; Rei D; Mair W; Laha JK; Cornwell ME; Cuny GD; Tsai LH; Steen JA; Kosik KS
    J Biol Chem; 2013 Jul; 288(30):22042-56. PubMed ID: 23737518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse model to study tau pathology related with tau phosphorylation and assembly.
    Engel T; Lucas JJ; Hernández F; Avila J
    J Neurol Sci; 2007 Jun; 257(1-2):250-4. PubMed ID: 17362999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.
    Irwin DJ; Cohen TJ; Grossman M; Arnold SE; Xie SX; Lee VM; Trojanowski JQ
    Brain; 2012 Mar; 135(Pt 3):807-18. PubMed ID: 22366796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.
    Arner A; Rockenstein E; Mante M; Florio J; Masliah D; Salehi B; Adame A; Overk C; Masliah E; Rissman RA
    J Alzheimers Dis; 2018; 61(3):1201-1219. PubMed ID: 29332037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
    Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
    Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter.
    Zhukareva V; Mann D; Pickering-Brown S; Uryu K; Shuck T; Shah K; Grossman M; Miller BL; Hulette CM; Feinstein SC; Trojanowski JQ; Lee VM
    Ann Neurol; 2002 Jun; 51(6):730-9. PubMed ID: 12112079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
    Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
    Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.
    Louis JV; Martens E; Borghgraef P; Lambrecht C; Sents W; Longin S; Zwaenepoel K; Pijnenborg R; Landrieu I; Lippens G; Ledermann B; Götz J; Van Leuven F; Goris J; Janssens V
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6957-62. PubMed ID: 21482799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models.
    Wang D; Fu Q; Zhou Y; Xu B; Shi Q; Igwe B; Matt L; Hell JW; Wisely EV; Oddo S; Xiang YK
    J Biol Chem; 2013 Apr; 288(15):10298-307. PubMed ID: 23430246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies.
    Nijholt DA; van Haastert ES; Rozemuller AJ; Scheper W; Hoozemans JJ
    J Pathol; 2012 Apr; 226(5):693-702. PubMed ID: 22102449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.